The estimated Net Worth of Pravin R Chaturvedi is at least $2.42 ezer dollars as of 17 May 2024. Dr Chaturvedi owns over 871 units of Jaguar Health Inc stock worth over $2,419 and over the last 3 years he sold JAGX stock worth over $0.
Dr has made over 5 trades of the Jaguar Health Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 871 units of JAGX stock worth $984 on 17 May 2024.
The largest trade he's ever made was exercising 3,333 units of Jaguar Health Inc stock on 5 April 2022 worth over $3,766. On average, Dr trades about 657 units every 97 days since 2022. As of 17 May 2024 he still owns at least 2,141 units of Jaguar Health Inc stock.
You can see the complete history of Dr Chaturvedi stock trades at the bottom of the page.
Dr. Pravin R. Chaturvedi Ph.D. is the Chair of Scientific Advisory Board & Acting Chief Scientific Officer at Jaguar Health Inc.
Dr D is 58, he's been the Chair of Scientific Advisory Board & Acting Chief Scientific Officer of Jaguar Health Inc since . There are 8 older and 5 younger executives at Jaguar Health Inc. The oldest executive at Jaguar Health Inc is James Bochnowski, 76, who is the Independent Chairman of the Board.
Pravin's mailing address filed with the SEC is C/O JAGUAR HEALTH, INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO, CA, 94104.
Over the last 10 years, insiders at Jaguar Health Inc have traded over $596,652 worth of Jaguar Health Inc stock and bought 670,772 units worth $1,311,594 . The most active insiders traders include Capital Partners, L.P.Sagar..., James J Bochnowski és Investments Ltd Burford Cap.... On average, Jaguar Health Inc executives and independent directors trade stock every 66 days with the average trade being worth of $27,901. The most recent stock trade was executed by Pravin R Chaturvedi on 17 May 2024, trading 871 units of JAGX stock currently worth $984.
jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/
Jaguar Health Inc executives and other stock owners filed with the SEC include: